Medical Dermatology
Conference Coverage
When patients get the travel bug, dermatologists should beware
NEW YORK – Asking the right questions is key to recognizing infectious diseases patients may have picked up during their travels.
Conference Coverage
Care of infants with ichthyosis requires ‘all hands on deck’
The neonatal period and early infancy are especially critical for patients with ichthyosis, because compromised barrier function increases risk...
Conference Coverage
Precise cause of pityriasis rosea remains elusive
Pityriasis rosea was recognized as early as 1798, yet its precise cause remains elusive.
From the Journals
One-third of sunscreens fall short of AAD recommendations
A survey of sunscreens sold at a major U.S. retailer found that the proportion that met AAD recommendations increased significantly since 2014,...
From the Journals
Subsequent squamous cell carcinoma risk higher in HIV patients with low CD4 count
HIV-infected people who have had a previous nonmelanoma skin cancer are at greater risk of subsequent SCC.
From the Journals
Isotretinoin patients need not postpone skin surgery
New data allows consensus to override old custom.
Conference Coverage
Study confirms new mutation, possible therapeutic target in epidermolysis bullosa
PORTLAND, ORE. – New research has uncovered “a new kid on the block” of genes underlying epidermolysis bullosa simplex (EBS), which may someday...
Under My Skin
My face is all red!
My grandson is almost 3. He is, of course, very advanced in many areas, including self-awareness.At the moment he is suffering from Fifth Disease...
Conference Coverage
Treatment challenges for lichen planopilaris
SYDNEY – Just over half of patients with lichen planopilaris in a medical record review responded to first-line therapies, but response rates...
News
FDA approves first specific treatment for giant cell arteritis
The approval of tocilizumab was made with breakthrough therapy and priority review designations.
Conference Coverage
Topical JAK inhibitor showed promise in facial vitiligo
PORTLAND - The effects of a topical JAK inhibitor on facial vitiligo in four patients were promising.